EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis

Youwen Zhu iD, Kun Liu iD, Hong Zhu iD, Shan Li, Dan Yuan

Therapeutic Advances in Medical Oncology · 2025-01 · 17

DOI: 10.1177/17588359241295544 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 07.01.2025. Verfasst von Youwen Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Project of Xiangya Hospital, Changsha Natural Science Foundation of Hunan Provincial of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Both the antibody–drug conjugate (ADC) enfortumab vedotin (EV) and programmed death-1 inhibitor pembrolizumab have been shown to provide survival benefits in patients previously treated with locally advanced or metastatic urothelial carcinoma (la/mUC). Cost-effectiveness is necessary to consider whether the increased efficacy of the two therapies will lead to higher prices for first-line treatment of previously untreated la/mUC.

Objectives

To guide the choice of EV plus pembrolizumab or chemotherapy for patients with previously untreated la/mUC.

Design

The cost-effective analysis.

Methods

A Markov model was developed to simulate the lifetime of patients with previously untreated la/mUC to assess the overall cost and efficacy of EV plus pembrolizumab and chemotherapy based on the EV-302/KEYNOTE-A39 trial. Primary outcomes included total cost, life-years (LYs), quality-adjusted LYs (QALYs), the incremental cost-effectiveness ratio (ICER), and incremental net health benefits at the USA and Chinese willingness-to-pay threshold of $150,000/QALY and $35,173/QALY, respectively. Model stability was examined through sensitivity and subgroup analyses.

Results

EV plus pembrolizumab and chemotherapy treatment regimens were associated with 2.07–2.16 and 1.04–1.06 QALYs with corresponding costs of $288,347–$532,362 and $24,773–$267,568, respectively. ICERs in the United States and China are $267,491/QALY and $254,339/QALY, respectively. The factors that most strongly influenced model outcomes in unidirectional sensitivity analyses were patient weight and the cost of EV. To achieve greater cost-effectiveness, EV costs would need to be reduced by over 75% and 10% in the United States and China, respectively.

Conclusion

While first-line EV plus pembrolizumab has significant health benefits compared to chemotherapy for patients with previously untreated la/mUC, this regimen is not cost-effective at the current price in the United States or China.

Schlagwörter

Stichwörter der Autor:innen

chemotherapycost-effectivenessenfortumab vedotinlocally advanced or metastatic urothelial carcinomapembrolizumab

Autor:innen und Institutionen

  • Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
  • Department of Oncology, Zhuzhou Second Hospital, Zhuzhou, Hunan 412000, China.

ORCID-Profile: Youwen Zhu, Kun Liu, Hong Zhu

Förderung

  • Clinical Research Project of Xiangya Hospital
  • Changsha Natural Science Foundation of Hunan Provincial of China

Zitieren

APA

Zhu, Y., Liu, K., Zhu, H., Li, S., & Yuan, D. (2025). Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359241295544

Vancouver

Zhu Y, Liu K, Zhu H, Li S, Yuan D. Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359241295544

BibTeX
@article{Zhu2025,
  author = {Zhu, Youwen and Liu, Kun and Zhu, Hong and Li, Shan and Yuan, Dan},
  title = {Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2025},
  volume = {17},
  doi = {10.1177/17588359241295544}
}
Kostenlos starten →